These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33661148)

  • 21. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.
    Hoang JK; Yang HI; Le A; Nguyen NH; Lin D; Vu VD; Chaung K; Nguyen V; Trinh HN; Li J; Zhang JQ; Chen CJ; Nguyen MH
    Medicine (Baltimore); 2016 Aug; 95(31):e4433. PubMed ID: 27495067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
    Lin CL; Lin YL; Liang KH; Chen LW; Chien CH; Hu CC; Huang TS; Shyu YC; Yeh CT; Chien RN
    Clin Ther; 2022 Mar; 44(3):403-417.e6. PubMed ID: 35469645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
    Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
    Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
    Liu M; Tseng TC; Jun DW; Yeh ML; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung M; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
    Hepatol Int; 2021 Feb; 15(1):71-81. PubMed ID: 33394321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
    Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
    Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
    Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
    Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
    Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
    Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
    Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
    Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.